The use of intravenous immunoglobulins in the treatment of neuromuscular disorders

Current Opinion in Neurology

Volumn 9, Issue 5, 1996, Pages 360-366

  Voltz, Raymond ^a   Hohlfeld, Reinhard ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY;

ACUTE KIDNEY FAILURE; ALOPECIA; ANAPHYLAXIS; ARTHRITIS; BRAIN VASOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING NEUROPATHY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SAFETY; EATON LAMBERT SYNDROME; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALAISE; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR NEUROPATHY; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEUROMUSCULAR DISEASE; NEUTROPENIA; PARANEOPLASTIC SYNDROME; POLYMYOSITIS; POLYNEUROPATHY; REVIEW; THROMBOEMBOLISM;

EID: 0029857355     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199610000-00008     Document Type: Review

References (72)

1. Thornton CA, Sallow M: Safety of intravenous immunoglobulin. Arch Neurol 1993, 50:135-136.
2. Voltz R, von Rosen F, Yousry T, Beck J, Hohlfeld R: Reversible encephalopathy with cerebral vasospasm in a GBS patient treated with iv immunoglobulin. Neurology 1996, 46:250-251.
3. Tam DA, Moton LD, Stroncek DF, Leshner RT: Neutropenia in 8 patient receiving intravenous immune globulin. J Neuroimmunology 1996, 64:175-178.
4. Lisak RP: Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1996, 135:85-88.
5. Oomes PG, van der Meché FGA, Kleyweg RP, and the Dutch Guiilain-Barré Study Group: Uver function disturbances in Guillain-Barré syndrome: a prospective longitudinal study In 100 patients. Neurology 1996, 46: 96-100.
6. Tamada K, Kohga M, Masuda H, Hattori K: Hemolytic anemia following high-dose Intravenous immunoglobulin administration. Acta Paediatr Jpn 1995, 37:391-393.
7. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ: Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995, 25:228-234.
8. Dalakas MC: Aseptic meningitis and intravenous immunoglobulin [Letter]. Ann Int Med 1995, 122:316-317.
9. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T: Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. New Engl J Med 1994, 331:1607-1611.
10. Schiano TD, Bellary SV, Black M: Possible transmission of hepatitis C virus infection with intravenous Immunoglobulin [Letter]. Ann Int Med 1995, 122:802-803.
11. Taliani G, Guerra E, Rosso R, Badolato MC, Luzi G, Sacco G, Lecce R, de Bac C, Aiuti F: Hepatitis C virus infection in hypogammaglobulinemic patients receiving long-term replacement therapy with intravenous immunoglobulin. Transfusion 1995, 35:103-107.
12. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Bisceglie AM, and the Hepatitis C Study Group: Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Ann Int Med 1995, 123:330-337.
13. Yang YH, Ngo C, Yeh IN, Uemura Y: Antibody Fc functional activity of intravenous immunoglobulin preparations treated with solvent-detergent for virus inactivation. Vox Sang 1994, 67:337-344.
14. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, Hammarstrom L, Jacobsen MB, Jonsson E, Moller G et at.: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs, Lancet 1995, 345:365-369.
15. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA, and the •• University Hospital Consortium Expert Panel for off-label use of polyvalent intravenously administered immunoglobulin preparations: Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995, 273:1865-1870. A consensus statement for off-label use of ivlg with specific recommendations for 53 indications and discussion of potential risks associated with ivlg.
16. Moghraby SA, AI-Momen AK, Gad-EI-Rab MO, Abdel-Gader AGM, AI-Meshari A: Immunoglobulin therapy for HLA-related recurrent fetal loss. Transfus Sci 1993, 14:183-187.
17. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36:838-845.
18. Lecky BRF: Gammaglobulin treatment in neurology - fundamentals and clinical applications. J Neurol Neurosurg Psychiatry 1994, 57(suppl): 1-75.
19. Ruiz de Souza V, Carreno MP, Kaveri SV, Ledur A, Sadeghi H, Cavaillon JM, Kazatchkine MD, Haeffner-Cavaillon N: Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995, 25:1267-1273.
20. Okitsu-Negishi S, Furusawa S, Kawa Y, Hashira S, Ito S, Hiruma F, Mizoguchi M, Yoshino K, Abe T: Suppressive effect of intravenous immunoglobulin on the activity of interleukin-1. Immunol Res 1994, 13:49-55.
21. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, • Glotz D, Kazatchkine MD: Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996, 97:865-869. An interesting contribution on the effects of ivlg on the cellular aspects of the immune response.
22. Blasczyk R, Westhoff U, Grosse-Wilde H: Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993, 341:789-790.
23. Perosa F, Rizzi R, Pulpito V, Dammacco F: Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? Clin Exp Immunol 1995, 99:16-20.
24. Hartung H-P, Pollard JD, Harvey GK, Toyka KV: Immunopathogenesis and •• treatment of Guillain-Barré syndrome - part I and II. Muscle Nerve 1995, 18:137-164. A comprehensive review of our current knowledge of GBS, including a discussion of all the therapeutic options available.
25. van der Meché, Schmitz PIM and the Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New Engl J Med 1992, 326: 1123-1129.
26. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K: Pilot trial of immunoglobulin versus plasma exchange in patients with Gulllain-Barré syndrome. Neurology 1996, 46:100-103.
27. The Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group: Comparison of plasma exchange, Intravenous immunoglobulin and plasma exchange followed by Intravenous immunoglobulin in the treatment of Guillain-Barré syndrome [Abstract]. Ann Neurol 1995, 38:972.
28. Dawson WB, Phillips LH: A comparison between ivlg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities. Clin Neuropharm 1995, 18: 377-390.
29. Visser LH, van der Meché FGA, van Doom PA, Meulstee J, Jacobs BC, Domes PG, Kleyweg RP, and the Dutch Guillain-Barré Study Group: Guillain-Barré syndrome without sensory loss (acute motor neuropathy) - a subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995, 118:841-847.
30. Heafield MTE, Gammage MD, Nightingale S, Williams AC: Idiopathic dysautonomia treated with Intravenous gammaglobulin. Lancet 1996, 347: 28-29.
31. Choudhary PP, Hughes RA: Long-term treatment of chronic inflammatory • demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995, 88:493-502. In this retrospective analysis of 105 CIDP patients treated with PE or ivlg for up to 60 months, ivlg was tolerated well, whereas PE was associated with more side effects.
32. Berger AR, Herskovitz S, Scelsa S: The restoration of ivlg efficacy by plasma exchange in CIDP. Neurology 1995, 45:1628-1629.
33. Taylor BV, Wijdicks EFM, Poterucha JJ, Weisner RH: Chronic inflammatory demyelinating polyneuropathy complicating liver transplantation. Ann Neurol 1995, 38:828-831.
34. Midroni G, Dyck PJ: Chronic inflammatory demyelinating polyradiculoneuropathy: unusual clinical features and therapeutic responses. Neurol 1996, 46:1206-1212.
35. Thompson N, Choudhary P, Hughes RAC, Quinlivan RM: A novel trial design to study the effect of Intravenous immunoglobulin in chronic Inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996, 243:280-285.
36. Berger AR, Herskovitz S, Kaplan J: Late motor involvement In cases presenting as 'chronic sensory demyelinating polyneuropathy'. Muscle Nerve 1995, 18:440-444.
37. Antoine JC, Mosnier JF, Convers P, Absi L, Laurent B, Michel D: Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry 1996, 60:188-190.
38. van der Meché FGA, van Doom PA: Guillain-Barré syndrome and chronic •• Inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995, 37(suppl 1) S14-S31 This paper is an excellent source of information on therapies for GBS and CIDP.
39. Gorson KC, Ropper AH: Treatment results in idiopathic chronic inflammatory demyelinating polyneuropathy [Abstract], Neurology 1996, 46:A380.
40. Krendel DA, Costigan DA, Hopkins LC: Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995, 52:1053-1061.
41. Bouche P, Moulonguet A, Younes-Chennoufi AB, Adams D, Baumann N, • Meininger V, Léger J-M, Said G: Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995, 59:38-44. The results of this study demonstrated that those patients showing a good response to ivlg therapy did not exhibit amyotrophy and had a positive GM1 antibody titer. The reponse was not correlated with the duration of disease.
42. van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, Jennekens FGI, Wokke JHJ: Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double-blind, placebocontrolled study. J Neurol Neurosurg Psychiatry 1995, 59:248-252.
43. van den Berg LH, Franssen H, Wokke JHJ: Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin. Neurology 1995, 45:987-988.
44. Wokke JHJ, van den Berg LH, Franssen H, Oey PL: The long-term effect of intravenous immunoglobulin treatment in patients with multifocal motor neuropathy [Abstract], Neurology 1996, 46:A381.
45. Zielasek J, Ritter G, Magi S, Hartung HP, Toyka KV: A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1. J Neurol 1994, 241:475-480.
46. van Schaik IN, Bossuyt PMM, Brand A, Vermeulen M: Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a metaanalysis. Neurology 1995, 45:1570-1577.
47. Malik U, Oleksowicz L, Lalov N, Cardo LJ: Intravenous y-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol 1996, 39:136-139.
48. Latov N: Pathogenesis and therapy of neuropathies associated with •• monoclonal gammopathies. Ann Neurol 1995, 37(suppl 1):S32-S42. An in-depth review of the pathogenesis of, and treatment options for, neuropathies associated with IgG- and IgM-MGUS, anti-myelin-associated glycoprotein and anti-GM1 antibody-associated neuropathies.
49. Glass JD, Cornblath DR: Chronic inflammatory demyelinating polyneuropathy and paraproteinemic neuropathies. Curr Opin Neurol 1994, 7:393-397.
50. Thornton CA, Griggs RC: Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994, 25: 260-268.
51. Simmons Z, Albers JW. Bromberg MB, Feldmann EL: Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculopathy, without and with monoclonal gammopathy. Brain 1995, 118:359-368.
52. Leger JM, Mariette X, Chastang C, Claveloa P, Louboutin JP, Bouche P, Brouet JC, and the IgM-Associated Polyneuropathy Study Group: A randomized trial comparing alpha-interferon and Intravenous immunoglobulin in polyneuropathy associated with IgM monoclonal gammopathy [Abstract], Neurology 1996, 46:A380.
53. + channels of peripheral nerves. Ann Neurol 1995, 38:714-722. This paper describes how three out of six neuromyotonia patients had antibodies that reacted with voltage-gated potassium channels. Passive transfer of patient IgG altered nerve excitability.
54. Layzer RB: Neuromyotonia: a new autoimmune disease [Editorial]. Ann Neurol 1995, 38:701-702.
55. van Engelen BGM, Benders AAGM, Gabreéls FJM, Veerkamp JH: Are muscle cramps In Isaacs' syndrome triggered by human immunoglobulin? [Letter]. J Neurol Neurosurg Psychiatry 1995, 59:393.
56. Edan G, Landgraf F: Experience with Intravenous immunoglobulin In myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 1994, 57: 55-56.
57. Lewis RA, Selwa JF, Lisak RP: Myasthenia gravis: immunological mechan•• isms and Immunotherapy. Ann Neurol 1995, 37(suppl 1):S51-S62. A very good reference source detailing current knowledge of the pathogenesis of, and therapeutic options for, myasthenia gravis.
58. Grob D, Simpson D, Mitsumoto H, Hoch B, Mokhtarian F, Bender A, Greenberg M, Koo A, Nakayama S: Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995, 45:338-344
59. Plotz PH: NIH conference - myositis: immunologic contributions to •• understanding cause, pathogenesis, and therapy. Ann Int Med 1995, 122:715-724. An up to date discussion of the most common myositis syndromes, including therapeutic considerations.
60. Cherin P, Herson S, Wechsler B, Piette J-C, Bletry O, Coutellier A, Ziza J-M, Godeau P: Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. Am J Med 1991, 91: 162-168.
61. Jann S, Beretta S, Moggio M, Adobbati L, Pellegrini G: High-dose intravenous human immunoglobulin in polymyositis resistant to treatment J Neurol Neurosurg Psychiatry 1992, 55:60-64.
62. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S: A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
63. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994, 94:1729-1735.
64. Sansome A, Dubowitz V: Intravenous immunoglobulin in juvenile dermatomyositis - four year review of nine cases. Arch Dis Child 1995, 72:25-28.
65. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, •• Rowland LP: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713 An excellent review on diagnostic criteria, pathogenesis and treatment of inclusion body myositis.
66. Dalakas MC, Illa I: Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. Ann Neurol 1995, 37:806-810.
67. Dalmau J and Posner JB: Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology 1994, 44:2241-2246.
68. Stübgen JP: Neuromuscular disorders in systemic malignancy and its •• treatment. Muscle Nerve 1995, 18:636-648. A very thorough review of the direct and paraneoplastic effects of neoplasms on the neuromuscular system. Possible side effects of radiation and chemotherapy are also reviewed.
69. Dalmau J, Graus F, Rosenblum MK, Posner JB: Anti-Hu-associated paraneoplastic encephalomyelltis/sensory neuronopathy: a clinical study of 71 patients. Medicine 1992, 71:59-72.
70. Counsell CE, McLeod M, Grant R: Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 1994, 44:1184-1185.
71. Phuphanich S, Brock C, Roberts WE, Prockop L: Neurologic improvement after a high-dose intravenous immunoglobulin therapy In paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody [Abstract]. Neurology 1996, 46:A129.
72. Petruzzi MJ, de Alarcon PA: Neuroblastoma-assoclated opsoclonusmyoclonus treated with intravenously administered Immune globulin G. J Pediatr 1995, 127:328-329.